Pemvidutide is a glp-1 / glucagon agonist used for weight loss / liver. Pemvidutide is a dual GLP-1 and glucagon agonist. In plain terms: it curbs appetite and nudges metabolism to burn more, studied for both weight loss and fatty-liver disease. It is still experimental.

How much water do I add to Pemvidutide?

You can reconstitute Pemvidutide with 0.5, 1, or 2 mL of bacteriostatic water. Each option produces a different concentration and syringe draw for the same dose. Use the calculator to see which is easiest to measure.

What does Pemvidutide cost per dose?

Cost per dose depends on vial size, price paid, and your dose. Enter your vendor's price in the Pemvidutide calculator to see cost per dose and monthly cost.

What is the reference dose for Pemvidutide?

The commonly referenced range is 1.2 up to 2.4 mg per week (trial doses), taken weekly. This is reference information, not a recommendation. Talk to a licensed clinician.

What are the side effects of Pemvidutide?

Reported side effects of Pemvidutide include: Stomach side effects.; Trial-only.. Severity and frequency vary by person and dose.

Who should not take Pemvidutide?

Pemvidutide is generally not appropriate for: No formal contraindications established; Pregnancy. Talk to a licensed clinician before starting.

New?New to peptides?Start here →

Decoding

Pemvidutide_Dosage, benefits & legal status

Also known as ALT-801

By the Peptide Decoding Editorial Team

Published July 22, 2026 · Updated July 25, 2026

An experimental weekly shot for weight loss and fatty liver.

Weight loss / liverGLP-1 / glucagon agonistInvestigational

InGLP-1 agonists

Common vial size10 mg

Dose1.2 up to 2.4 mg per week (trial doses)

FrequencyWeekly

RouteUnder the skin (subcutaneous)

StatusInvestigational

MixYour choice, calculate it

CycledNot cycled in the trials

Common vial size is what vendors typically sell, not a recommendation. Enter your own vial in the calculator.

What is Pemvidutide?

Plain language first. The technical label stays, but it never stands alone.

Overview

It curbs appetite and nudges metabolism to burn more, studied for both weight loss and fatty-liver disease. It is still experimental.

The technical version

Pemvidutide is a dual GLP-1 and glucagon agonist.

What it's used for

An experimental weekly shot for weight loss and fatty-liver disease, working on two pathways.

How does Pemvidutide work?

What it does in the body, and where.

Pemvidutide combines GLP-1 with glucagon, and is being developed for liver disease as much as for weight.

01
GLP-1 reduces intake, glucagon raises expenditure
The same two-lever design as survodutide.
02
Liver fat is the primary target
Glucagon acts directly on the liver, which is why this pairing keeps being tested in fatty liver disease rather than only in obesity.
03
Still investigational
Phase 2 results only.

Receptors

Hits 2 receptors at once.

What else is it used for?

Each use below carries its own evidence level. Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.

Weight lossInvestigational
Fatty liver disease (MASH)Investigational

The published record

Research index

Records indexed for Pemvidutide

25 in humans, 6 of them original studies.

16 registered trials, 5 with posted results.

Browse the records

In animalsPro

In the labPro

ReviewsPro

Senior author sharePro

Counted from Europe PMC indexing, not read by a person. Human means indexed under humans, which includes reviews and work on human cells. Original studies exclude reviews and lab work on human cells.Last updated 12 September 2026.

Compound field notes

At a glance

Four things to know about Pemvidutide

Evidence

Investigational

How much, and do you cycle it?

The range, and whether you take breaks.

1.2 up to 2.4 mg per week (trial doses), weekly. Not cycled in the trialsTrial dose

Given continuously for the whole study period: MOMENTUM, 48 weeks. The dose is stepped up at the start, which is a ramp rather than a cycle, and no trial in this class built in a planned break.

Compare this against the whole library →

How long does it stay in the body?

The half-life, and where the figure comes from.

About 110 hoursTrial protocol

From an investor presentation rather than a published pharmacokinetic paper.

Source: Altimmune phase 1 corporate disclosure, September 2021. ADA 2022 abstract 334-OR

You can compare this against the whole library to see where it sits.

How do I dose and price it?

Enter your vial and your dose. Pick a mix. We show the draw and the cost.

The vial holds a fixed amount of drug. Adding more water does not make more drug, it just spreads it thinner, so you draw a bigger number on the syringe for the same dose.

Your vial size (mg)

Printed on the vial.

What you paid per vial

Used for cost per dose only.

Your dose (mg)

Commonly referenced range: 1.2 up to 2.4 mg per week (trial doses)Trial dose

Choose your mix

0.5 mL water6units · 20 mg/mL

Half a 100-unit syringe

1 mL water12units · 10 mg/mL

One full 100-unit syringe

Easiest

2 mL water24units · 5 mg/mL

Two full 100-unit syringes

your own mL

units · —

Enter your own volume

Measuring the water1 mL = one full 100-unit syringe.

Your draw

24 / 100 units

Full calculator with reorder date →Read a syringe →

How do you store it?

Before mixing, and after.

Dry powder in the freezer or fridge. Once mixed, fridge, and use within about a month.

Unmixed lyophilized Pemvidutide keeps for a long time cold. Once you add water the clock starts: most reconstituted vials hold up for roughly 28 to 30 days at fridge temperature. Keep it out of light, and do not freeze it after mixing.

What are the side effects and cautions?

Known cautions and warnings for this compound.

Who should avoid it

Check these before anything else.

No formal contraindications established
Pregnancy

Stop and get help

These are emergencies. Seek care.

Vomiting that will not stop
Severe stomach pain that spreads to your back
Signs of an allergic reaction such as face or throat swelling, hives, or trouble breathing

Common effects

Expected, and usually mild.

Nausea and vomiting are the main effects, mostly mild to moderate
Low rates of diarrhea and constipation
The manufacturer reports no meaningful rise in heart rate, which is a company-reported claim

Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.

Is Pemvidutide approved?

And where the numbers on this page come from.

No. Pemvidutide is not approved anywhere and is currently in company-run clinical trials. There is no legal route to obtain it outside a trial.

Approval status
Investigational
Route
Under the skin (subcutaneous)
Checked
September 2026

What has happened recently

We have not yet written a full regulatory note for this compound. The status above is current as of the date shown.

You can compare this against the whole library, or read how to check a seller.

DoseFrom published clinical trials. Not approved by a regulator for this dose.
Vial sizeFrom what vendors typically list; not a recommendation.
Sources
Altimmune, topline results from the 48-week MOMENTUM phase 2 obesity trial of pemvidutide Altimmune, MOMENTUM phase 2 topline results deck
Reviewed8 September 2026

What else is like Pemvidutide?

Others in GLP-1 agonists, side by side.

If you're weighing Pemvidutide, it's worth reading Zovaglutide (ZT-002), Dulaglutide (Trulicity), and Exenatide (Byetta / Bydureon) in the same class.

YOU ARE HERE

PEMVI29 residues

Pemvidutide

An experimental weekly shot for weight loss and fatty liver.

Investigational

Dose: 1.2 up to 2.4 mg per week (trial doses)
How often: Weekly

ZOVA

Zovaglutide (ZT-002)

An experimental once-a-month weight-loss shot.

Investigational

Dose: 80 up to 160 mg per month (trial doses)
How often: Monthly

DULA

Dulaglutide (Trulicity)

A weekly GLP-1 shot for diabetes, with far less weight loss than the famous ones.

FDA-approved

Dose: 0.75 up to 4.5 mg per week (start low, increase slowly)
How often: Weekly

EXEN

Exenatide (Byetta / Bydureon)

The first GLP-1 drug, found in lizard venom, now mostly retired.

FDA-approved

Dose: 2 mg per week (the weekly form)
How often: Weekly

How Pemvidutide compares to other GLP-1 peptides

Compare all 15 GLP-1 peptides

Guides for this compound

How to Reconstitute a Peptide
Mix peptide powder with bacteriostatic water, step by step.
How to Read an Insulin Syringe
Read the units, convert to millilitres, and draw the exact dose.
mcg vs mg: The Peptide Dosing Mistake to Avoid
Your vial says mg and your protocol says mcg. Here is the conversion and how to check it.
How to Read a Peptide COA
What the purity number does and does not tell you, and how to spot an edited report.
How to Vet a Peptide Vendor
Independent COAs, HPLC purity, and the red flags that mean walk away.

Sources

Altimmune, topline results from the 48-week MOMENTUM phase 2 obesity trial of pemvidutide(2023)
391 participants. Mean weight loss at week 48 was 10.3 percent at 1.2 mg, 11.2 percent at 1.8 mg and 15.6 percent at 2.4 mg, against 2.2 percent on placebo.
Altimmune, MOMENTUM phase 2 topline results deck(2023)
Arm sizes were roughly 97 to 99 each. The body composition analysis behind the lean-mass claim covered 50 participants, and reported 78.1 percent of weight loss as fat and 21.9 percent as lean mass.

Last reviewed 8 September 2026

Beyond these, 34 records are indexed. Browse the records